Abstract
During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly (ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
Keywords: Polymer, cancer, diabetes, conjugates, antiviral, disease.
Current Pharmaceutical Design
Title:Polymer Drug Conjugates: Recent Advancements in Various Diseases
Volume: 22 Issue: 19
Author(s): Jasbir Singh, Sapna Desai, Snehlata Yadav, Balasubramanian Narasimhan and Harmeet Kaur
Affiliation:
Keywords: Polymer, cancer, diabetes, conjugates, antiviral, disease.
Abstract: During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly (ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
Export Options
About this article
Cite this article as:
Singh Jasbir, Desai Sapna, Yadav Snehlata, Narasimhan Balasubramanian and Kaur Harmeet, Polymer Drug Conjugates: Recent Advancements in Various Diseases, Current Pharmaceutical Design 2016; 22 (19) . https://dx.doi.org/10.2174/1381612822666160217125515
DOI https://dx.doi.org/10.2174/1381612822666160217125515 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry The Leptin System: A Potential Target for Sepsis Induced Immune Suppression
Endocrine, Metabolic & Immune Disorders - Drug Targets Modifiers of Hearing Impairment in Humans and Mice
Current Genomics Editorial [Hot Topic: Protein Kinase Inhibitors for the Treatment of Inflammatory Disease (Guest Editor: Mark R. Player)]
Current Topics in Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Anti-Cancer Agents in Medicinal Chemistry The Identification, Characterization and Optimization of Small Molecule Probes of Cysteine Proteases: Experiences of the Penn Center for Molecular Discovery with Cathepsin B and Cathepsin L
Current Topics in Medicinal Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Cyclodextrin-Based Delivery Systems for Arthritic Diseases: From Development to Experimental Therapeutics
Current Pharmaceutical Design Role of Matrix Metalloproteinases in Animal Models of Ischemic Stroke
Current Vascular Pharmacology Insight into the Epigenetics of Alzheimer's Disease: A Computational Study from Human Interactome
Current Alzheimer Research Pain-Relief Medication and Risk of Fractures
Current Drug Safety Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Cytokines in Sleep Regulation
Current Pharmaceutical Design Unusual Cerebral Involvement of Rheumatoid Arthritis Mimicking a Tumor
Current Medical Imaging Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents
Current Medicinal Chemistry Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design